DMII.US Drugs Made In America Acquisition II Corp. Ordinary Shares

Financial Services Capital Markets USA Stocks
10.24 USD
Close of Nov 14, 2026
9.86 10.33
Market cap
USD 652M
P/E
34.1x
P/B
1.32x
ROE
3.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is DMII.US undervalued?

Graham number
Price10.24
Graham value7.25
Premium41.3%

DMII.US trades 41.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Drugs Made In America Acquisition II Corp. Ordinary Shares fundamental analysis

No fundamental analysis for Drugs Made In America Acquisition II Corp. Ordinary Shares yet.

Drugs Made In America Acquisition II Corp. Ordinary Shares stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Drugs Made In America Acquisition II Corp. Ordinary Shares

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.

Full company profile